Capricor Therapeutics Gets $4.2M Grant

Los Angeles-based Capricor Therapeutics, a biotechnology firm developing treatments for cardiac and other conditions, has been awarded a $4.2M grant from the National Institutes of Health. The company said the grant will go to study CAP-2003 (cardiosphere-derived cell exosomes) for hypoplastic left heart syndrome (HLHS). HLHS is a congenital defect of the heart which often results in heart failure. Capricor is led by President and CEO Linda Marban, Ph.D.